Effectiveness and risk of ARB and ACEi among different ethnic groups in England: A reference trial (ONTARGET) emulation analysis using UK Clinical Practice Research Datalink Aurum-linked data
These results demonstrate variation in drug effects of ACEi and ARB for some outcomes by ethnicity and suggest the potential for adverse consequences from current UK guideline recommendations for ARB in preference to ACEi for Black individuals.
Authors
- Angel Y. S. Wong (ORCID: https://orcid.org/0000-0002-8618-7333)
- Kevin Wing (ORCID: https://orcid.org/0000-0003-2335-9641)
- Paris J Baptiste (ORCID: https://orcid.org/0000-0002-2565-8525)
- Shrikant I. Bangdiwala (ORCID: https://orcid.org/0000-0002-3111-0689)
- Emma Powell (ORCID: https://orcid.org/0000-0001-9427-9468)
- Johannes F.E. Mann (ORCID: https://orcid.org/0000-0002-3154-5332)
- Koon Kang Teo (ORCID: https://orcid.org/0000-0002-3731-0956)
- Marianne Cunnington (ORCID: https://orcid.org/0009-0002-2398-2281)
- Anna Schultze
- Catherine M. Clase (ORCID: https://orcid.org/0000-0002-4538-5958)
- Elizabeth Williamson (ORCID: https://orcid.org/0000-0001-6905-876X)
- Laurie A. Tomlinson (ORCID: https://orcid.org/0000-0001-8848-9493)
- Clémence Leyrat (ORCID: https://orcid.org/0000-0002-4097-4577)
- Peggy Gao
Institutions
- Queen Mary University of London (GB)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Population Health Research Institute (CA)
- London School of Hygiene & Tropical Medicine (GB)
- München Klinik Schwabing (DE)
- Institute of Group Analysis (GB)
- Impact (CA)
- McMaster University (CA)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1371/journal.pmed.1004465
- Citations
- 6
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.41
Funders
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- London School of Hygiene and Tropical Medicine
- Wellcome Trust
- National Institute for Health and Care Excellence
- Fresenius Medical Care North America
- Bayer HealthCare
- Novo Nordisk
- Astellas Pharma
- LEO Pharma
- Medical Research Council
- Relypsa